Immunoblotting Analysis of Intracellular PD-L1 Levels in Interferon-γ-Treated Ovarian Cancer Cells Stably Transfected with Bcl3 shRNA

Padmanabhan, Sveta; Zou, Yue; Vancurova, Ivana

doi:10.1007/978-1-0716-0247-8_18

Cited by 6 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like most types of cancer, OC lacks clinical symptoms at its early stages, therefore, most patients have proceeded to the advanced stage at the time of diagnosis (4)(5)(6). Moreover, the pathogenesis of OC remains unclear, and there are no specific therapies for OC, leading to an adverse prognosis of the disease (7)(8)(9). Thus, it is of great importance to develop new therapeutic strategies to improve the therapeutic efficacy of OC and to increase the 5-year survival rate of OC patients.…”

Section: Introductionmentioning

confidence: 99%

Ligustrazine inhibits the proliferation and migration of ovarian cancer cells via regulating miR-211

2021

View full text Add to dashboard Cite

Ovarian cancer (OC) is a commonly diagnosed female cancer. Ligustrazine (LSZ), a natural compound, has been reported to exert anti-cancer activity, although the mechanisms underlying the anticancer effects are not clear. This study investigated the impact of LSZ on cell proliferation and migration by regulating mircorna-211(miR-211) expression using the human ovarian cancer SK-OV-3 and OVCAR-3 cell lines. OC cells were treated with 0, 0.5, 1, and 2 mM LSZ, and quantitative real-time PCR was utilized to measure miR-211 levels in SK-OV-3 and OVCAR-3 cells with different treatment. Moreover, to further confirm the roles of miR-211 in LSZ induced anti-tumor effects, miR-211 expression was inhibited by transfection of miR-211 inhibitors in SK-OV-3 cells. Cell proliferation of transfected cells was evaluated using the CCK-8 and colony formation assay. The scratch assay was employed to assess cell migration and transwell assay was performed for evaluating the cell invasion. Protein levels of epithelial-mesenchymal transition (EMT) markers were determined by western blotting. We found that LSZ inhibited the viability, proliferation, migration and invasion ability of SK-OV-3 and OVCAR-3 cells in a dose-dependent manner; moreover, LSZ could significantly increase the expression of miR-211 in both SK-OV-3 and OVCAR-3, and knockdown of miR-211 in SK-OV-3 cells partially abrogated the anti-tumor behavior of LSZ by promoting the viability, proliferation, migration, invasion and EMT of SK-OV-3 cells. Thus, we found that Ligustrazine can inhibit the proliferation and migration of ovarian cancer cells via regulating miR-211. Our study suggests that LSZ might be a potential and effective treatment for OC.

show abstract

Section: Introductionmentioning

confidence: 99%

Ligustrazine inhibits the proliferation and migration of ovarian cancer cells via regulating miR-211

2021

View full text Add to dashboard Cite

show abstract

“…Intriguingly, numerous studies have established that a variety of biological factors have the ability to enhance PD-1/PD-L1 expression. Padmanabhan et al uncovered that IFNγ induced tumoral PD-L1 and proto-oncogene B-cell lymphoma-3 (BCL3) expression in ovarian cancer cell culture [ 119 ]. Additionally, it was hypothesized that PD-L1 expression is influenced by BCL3, as stable BCL3 knockdown cell lines exhibited significantly decreased levels of PD-L1.…”

Section: Pd-1 Based Combinatorial Approachesmentioning

confidence: 99%

“…Additionally, it was hypothesized that PD-L1 expression is influenced by BCL3, as stable BCL3 knockdown cell lines exhibited significantly decreased levels of PD-L1. Furthermore, the authors propose that targeting BCL3 may provide a novel means to modulate PD-L1 expression, as their results suggest that IFNγ induction of PD-L1 is facilitated by BCL3 [ 119 ]. In agreement with these results, a study by Zou et al found that BCL3 promotes IFNγ-induced expression of PD-L1 and that the inhibition of PD-L1 leads to reduced proliferation in BCL3-overexpressing cells, corroborating that PD-L1 is a target of BCL3 [ 120 ].…”

Section: Pd-1 Based Combinatorial Approachesmentioning

confidence: 99%

See 1 more Smart Citation

The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer

James

Woodman

DiSilvestro

et al. 2020

Cancers

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, with an overall 5-year survival of only 47%. As the development of novel targeted therapies is drastically necessary in order to improve patient survival, current EOC clinical trials have heavily focused on immunotherapeutic approaches, centered upon programmed cell death 1 (PD-1) inhibitors. While PD-1 monotherapies have only exhibited modest responses for patients, it has been theorized that in order to enhance EOC patient response to immunotherapy, combinatorial regimens must be investigated. In this review, unique challenges to EOC PD-1 response will be discussed, along with a comprehensive description of both preclinical and clinical studies evaluating PD-1-based combinatorial therapies. Promising aspects of PD-1-based combinatorial approaches are highlighted, while also discussing specific preclinical and clinical areas of research that need to be addressed, in order to optimize EOC patient immunotherapy response.

show abstract

“…IFN-γ was an agent that increased the expression of Bcl3 in OC cells, leading to increased transcriptional activity of PD-L1. PD-L1 expression was significantly reduced in OC cells stably transfected with Bcl3 shRNA ( 63 , 64 ).…”

Section: The Roles Of Ifns In Ovarian Cancer Immunitymentioning

confidence: 99%

The role of interferons in ovarian cancer progression: Hinderer or promoter?

Liu

Wang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Ovarian cancer (OC) is a common gynecologic malignancy with poor prognosis and high mortality. Changes in the OC microenvironment are closely related to the genesis, invasion, metastasis, recurrence, and drug-resistance. The OC microenvironment is regulated by Interferons (IFNs) known as a type of important cytokines. IFNs have a bidirectional regulation for OC cells growth and survival. Meanwhile, IFNs positively regulate the recruitment, differentiation and activation of immune cells. This review summarizes the secretion and the role of IFNs. In particular, we mainly elucidate the actions played by IFNs in various types of therapy. IFNs assist radiotherapy, targeted therapy, immunotherapy and biotherapy for OC, except for some IFN pathways that may cause chemo-resistance. In addition, we present some advances in OC treatment with the help of IFN pathways. IFNs have the ability to powerfully modulate the tumor microenvironment and can potentially provide new combination strategies for OC treatment.

show abstract

Immunoblotting Analysis of Intracellular PD-L1 Levels in Interferon-γ-Treated Ovarian Cancer Cells Stably Transfected with Bcl3 shRNA

Cited by 6 publications

References 11 publications

Ligustrazine inhibits the proliferation and migration of ovarian cancer cells via regulating miR-211

Ligustrazine inhibits the proliferation and migration of ovarian cancer cells via regulating miR-211

The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer

The role of interferons in ovarian cancer progression: Hinderer or promoter?

Contact Info

Product

Resources

About